SPARC

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE232I01014
NSEID: SPARC
BSEID: 532872

INR

152.85

0.9 (0.59%)

BSENSE

Dec 05

BSE+NSE Vol: 1.8 cr

Click here to access the older version

Company CV

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd

Small Cap

Pharmaceuticals & Biotechnology

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company.

Company Coordinates

Company Details

Sun Pharma Advanced Res Centre, Akota Road Akota Vadodara Gujarat : 390020

Tel: 91-265-2330815/2339257

http://www.sparc.life

secretarial@sparcmail.com

Registrar Details

Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai

Capital Structure

Present Equity Capital

INR 32.45 Cr

Number of Shares

32.45 Cr

Face Value

INR 1.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

06-Jan-2023

32.45

49192121

Conversion of Warrants

08-Nov-2022

27.53

3450501

Conversion of Warrants

08-Nov-2022

27.53

3450501

Conversion of Warrants

21-Mar-2022

27.19

8426966

Conversion of Warrants

25-Aug-2021

26.35

1404494

Conversion of Warrants

03-Aug-2018

25.6

25.60

5050505

Conversion of Warrants

15-Dec-2017

25.09

4040404

Conversion of Warrants

18-Aug-2017

24.69

Allotment of Equity To Others

11-Nov-2016

24.69

191

Allotment of Equity To Others

29-Jul-2016

24.69

4351

Reissue of Forfeited Shares

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 8 Schemes (1.01%)

FIIs

Held by 25 FIIs (1.76%)

Promoter with highest holding

Shanghvi Finance Private Limited (42.28%)

Highest Public shareholder

Sun Pharmaceutical Industries Key Employees Benefit Trust (3.18%)

Individual Investors Holdings

18.94%

Board of Directors

Period

Management

Designation

Remuneration

T Rajamannar

Director

3.6 lacs

Sudhir V Valia

Director

6.9 lacs

Bhavna Doshi

Independent Director

6.3 lacs

Ferzaan Engineer

Independent Director

5.4 lacs

Robert Spiegel

Independent Director

5.4 lacs

Dilip S Shanghvi

Chairman (Non-Executive)

3.3 lacs

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

No Data Available for Raw Material Segmentation

No Data Available

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

License Fees/Royalty on Technology/R&D Services

182.87

100.00%

License Fees/Royalty on Technology/R&D Services

Stock DNA

Revenue and Profits:

Net Sales:

8 Cr

(Quarterly Results - Sep 2025)

Net Profit:

-76 Cr

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 4,912 Cr (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.21

Return on Equity

77.47%

Price to Book

-14.32